Mankind Pharma has announced a strategic collaboration with OpenAI, aimed at integrating artificial intelligence across its entire value chain. The move marks one of the first times an Indian pharmaceutical company has committed to fully embedding advanced AI into its core operations.

The company plans to adopt OpenAI Enterprise tools in multiple functions including field force enablement, digital marketing, research and development (R&D), manufacturing, and medical affairs. GPT-powered dashboards will be used to deliver real-time, data-driven insights across R&D, supply chain, and commercial operations.

Since July 2025, Mankind Pharma has already deployed a number of custom GPT models across its workforce. Teams in sales and marketing are using them to sharpen messaging, enable faster multilingual communication, improve demand planning, and strengthen procurement. The tools have also been used to monitor field force performance in real time.

Arjun Juneja, Chief Operating Officer at Mankind Pharma, said that working with OpenAI represents a pivotal shift: “By integrating advanced AI into our core operations, we’re enabling our teams to move faster, work smarter, and unlock insights that drive real-world impact — whether it’s in field force effectiveness, supply chain agility, or R&D acceleration.”

Oliver Jay, Managing Director (International) at OpenAI, added that the adoption of ChatGPT Enterprise across Mankind’s functions demonstrates the practical role AI can play in regulated industries. He emphasised the importance of applying AI responsibly, safely, and in a compliant manner to support innovation.

This collaboration comes at a time when many Indian drugmakers are increasing investment in R&D and seeking to diversify into novel therapies, biosimilars, and complex generics. Mankind’s initiative is a clear signal that innovation and digital leadership are becoming as important as scale and cost in India’s pharma industry.